Abstract: d-Containing GABA A receptors are located extrasynaptically and mediate tonic inhibition. Their involvement in brain physiology positions them as interesting drug targets. There is thus a continued interest in establishing reliable recombinant expression systems for d-containing GABA A receptors. Inconveniently, the recombinant expression of especially a 4 b 1/3 d receptors has been found to be notoriously difficult, resulting in mixed receptor populations and/or stoichiometries and differential pharmacology depending on the expression system used. With the aim of developing a facile and robust 96-well format cellbased assay for extrasynaptic a 4 b 1/3 d receptors, we have engineered and validated a HEK293 Flp-In TM cell line stably expressing the human GABA A d-subunit. Upon co-transfection of a 4 and b 1/3 subunits, at optimized ratios, we have established a welldefined system for expressing a 4 b 1/3 d receptors and used the fluorescence-based FLIPR Membrane Potential (FMP) assay to evaluate their pharmacology. Using the known reference compounds GABA and THIP, ternary a 4 b 1/3 d and binary a 4 b 1/3 receptors could be distinguished based on potency and kinetic profiles but not efficacy. As expected, DS2 was able to potentiate only d-containing receptors, whereas Zn 2+ had an inhibitory effect only at binary receptors. By contrast, the hitherto reported d-selective compounds, AA29504 and 3-OH-2'MeO6MF, were non-selective. The expression system was further validated using patch clamp electrophysiology, in which the superagonism of THIP was confirmed. The established FMP assay set-up, based on transient expression of human a 4 and b 1/3 subunits into a d-subunit stable HEK293 Flp-In TM cell line, portrays a simple 96-well format assay as a useful supplement to electrophysiological recordings on d-containing GABA A receptors.
c-Aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the mammalian brain, mediating its effect at ionotropic GABA A receptors and metabotropic GABA B receptors. The ionotropic GABA A Rs are hetero-or homopentameric ligand-gated chloride conducting ion channels composed of 19 homologous subunits (a [1] [2] [3] [4] [5] [6] , b 1-3 , c 1-3 , d, e, h, p and q 1-3 ), forming receptors showing distinct brain regional distribution and pharmacology depending on the subunit composition [1] . GABA A receptors containing the d-subunit are located at extrasynaptic sites and mediate tonic inhibition [2] . Typically, the d-subunit combines with a 4/6 -subunits and b 1-3 -subunits, forming receptors with high sensitivity to GABA, and is activated by the ambient spillover concentration of GABA from the synapse [3, 4] .
GABA A receptors, especially a 4 d-containing receptors, are highly expressed in discrete brain regions, notably the hippocampus, striatum and cortex [5] . These have received a great deal of attention in the last decades as they represent potential drug targets for treatment of diseases such as epilepsy, stroke, mood and addiction disorders [4, [6] [7] [8] .
In spite of the number of studies, the precise pharmacology of the d-containing GABA A receptors remains uncertain. Although not exclusively, studies performed on a 4 b 1/3 d expressed in Xenopus laevis oocytes have reported biphasic GABA concentration-response curves with EC 50 values in the low nanomolar and low micromolar range, respectively, [9] [10] [11] whereas monophasic GABA concentration-response curves with EC 50 values in the low micromolar range have typically been observed for receptors expressed in HEK cells [12, 13] . Explanations for these differences may relate to both differences in the biochemistry of the expression system, differences in transfection ratios and the species of the used subunits [14] [15] [16] [17] . The impact of the transfection ratios and subunit arrangement has been studied by various groups, but with conflicting results. A study by You and Dunn [15] showed the transfection ratio to influence the pharmacology greatly, whereas Wang et al. [18] reported of no effect of the transfection ratio on the pharmacology.
Moreover, it is known that d-containing GABA A receptors are notoriously difficult to express consistently in recombinant systems, and thus, there is a concern for interfering signals from binary ab or homomeric b receptors [13, 19] , which may influence the pharmacology. The majority of studies have compared the pharmacology of the d-containing receptors to the corresponding c 2 -containing receptors to confirm the incorporation of the d-subunit in the receptor complex, but often not ruled out a possible contribution from ab receptors and or homomeric b receptors [13, 20] , although these have different ligand sensitivity to zinc (Zn 2+ ) and different rates and extents of desensitization compared to ternary receptors [9, 21, 22] .
Another way to distinguish a 4 b and a 4 bd recombinant receptors is by the use of subtype-selective compounds for d-containing receptors; however, only a few have been reported so far, including THIP [21] , DS2 [20] , AA29504 [23] and 3-OH-2'MeO6MF [24] . To the best of our knowledge, no d-selective antagonists have been reported. Traditionally, recombinant GABA A receptors are studied using electrophysiology, typically either by whole-cell patch clamp recordings on mammalian cell lines or two-electrode voltage clamp on Xenopus laevis oocytes [22, 25] . Both of these methods are labour-intensive and thus not very high throughput, making them less suitable for fast and easy obtainment of data or for screening purposes. An alternative, more indirect method is based on agonist-induced changes in membrane potential which may be measured by the addition of a fluorescent dye in the so-called FLIPR membrane potential (FMP) assay. This assay has previously been reported as a method to study recombinant abc and abd GABA A receptors expressed in cell lines [20, 26, 27] . Particularly, in a study by Wafford et al., [20] a stably expressing a 4 b 3 d cell line in the L(tk À ) fibroblast cell line was used and led to the identification of DS2, a highly useful and selective tool compound for d-containing receptors.
Thus, the aim of this study was to develop a robust, reliable cell-based assay for recombinant a 4 b 1/3 d GABA A receptors that could constitute a suitable alternative with higher throughput than electrophysiology. Using a newly established HEK293 Flp-In TM cell line, stably expressing the human GABA A d-subunit to high levels, and conveniently apt for transfection with wild-type or mutant a or b subunits for transient expression introduces a useful method for studying the molecular pharmacology of abd GABA A receptors in general.
Materials and Methods
Chemicals. Dulbecco's modified Eagle medium (DMEM) with GlutaMAX-I, Dulbecco's phosphate-buffered saline (DPBS), foetal bovine serum (FBS), penicillin-streptomycin, hygromycin B, trypsin and Hank's balanced salt solution (HBSS) were purchased from Life Technologies (Paisley, UK). PolyFect transfection reagent was purchased from Qiagen (West Sussex, UK). Poly-D-lysine (PDL), HEPES (4-(2-hydroxy-ethyl)-piperazine-1-ethanesulfonic acid), DMSO (dimethyl sulfoxide) and compounds were purchased from Sigma-Aldrich (St. Louis, MO, USA). Picrotoxin, etomidate ((R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester), DS2 (4-chloro-N-[2-(2-thienyl)imidazo[1,2-a]pyridin-3-yl]benzamide) and AA29504 ([2-amino-4-(2,4,6-trimethylbenzylamino)-phenyl]-carbamic acid ethyl ester) were purchased from Tocris Bioscience (Bristol, UK). THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c] pyridin-3-ol hydrochloride) was a gift from Dr. Bjarke Ebert (Lundbeck A/S, Valby, Denmark) and 3-OH-2 0 MeO6MF (3-hydroxy-2 0 -methoxy-6-methylflavone) was a gift from Dr. Mary Chebib (University of Sydney, Sydney, Australia) ( fig. 1 ). The FMP blue dye was purchased from Molecular Devices (Sunnyvale, CA, USA). Stocks of 3-OH-2 0 MeO6MF, AA29504, DS2, etomidate and picrotoxin were dissolved in DMSO to a final concentration of maximum 1% DMSO, which was the maximum concentration tolerated in the FMP assay, whereas GABA and THIP were dissolved in H 2 O.
Subcloning of a 4 , b 1 , b 3 and d GABA A receptor subunits and NPBWR2. With the aim of obtaining efficient transient expression of the human a 4 and b 1 GABA A subunits, these were subcloned into the pUNIV expression vector (Addgene, Cambridge, MA, USA [28] ). To do so, the DNA sequences encoding the a 4 and b 1 subunits (originally in pcDNA1 and pcDM8 expression vectors) were amplified by standard PCR using the primers listed below, with forward primers containing the alfalfa mosaic virus (AMV) sequence and the XhoI restriction site, and reverse primers containing the MluI restriction site. The sequence of the cDNA and the absence of mutations were confirmed by DNA sequencing (GATC Biotech AB, Konstanz, Germany). a 4 forward primer:
The subcloning of the b 3 subunit into the pcDNA3.1 vector has been described previously [27] .
For the purpose of creating a stable human d-expressing cell line, the d-subunit was subcloned into the pcDNA5/FRT vector from its original vector using the pcDNA5/FRT/V5-His TOPO â TA Expression Kit (Invitrogen, Paisley, UK), and with the utility of the unique restriction enzymes NheI and KpnI. The original d-construct was the same as used by others [21] and contained in overview: the bovine a 1 signal peptide (Genbank accession number NM_174540), inserted to enhance expression, followed by a c-myc epitope (EQKLISEEDL), and the human GABRD cDNA (corresponding to amino acids 46-452; Genbank accession number NP_000806.2).
For control experiments, the G protein-coupled receptor NPBWR2 was used as this receptor is completely unrelated to GABA A receptors. The NPBWR2 cDNA (Genbank accession no. NM_005286.2) was purchased from Origene (Rockville, MD, USA). The cDNA was subcloned into the pcDNA5/FRT vector using NheI and KpnI restriction sites as described for the HEK-d cell line.
Cell culturing and expression of GABA A receptors. HEK293 Flp-In TM cells were cultured in DMEM with GlutaMAX-I supplemented with 10% FBS and 1% penicillin-streptomycin and kept in an incubator at 37°C and 5% CO 2 . Transfections with cDNA constructs were performed using PolyFect transfection reagent following the manufacturer's protocol, however, with half the recommended volume of PolyFect. A stable cell line expressing the human d-subunit was generated by co-transfection of the d-subunit (pcDNA5/FRT) and pOG44 recombinase expression plasmid (Invitrogen) into the HEK293 Flp-In TM cell line (Invitrogen) as per the manufacturer's protocol (hereafter referred to as HEK-d). As control cell line, the HEK293 Flp-In TM cell line was transfected with a construct encoding the G protein-coupled peptide receptor NPBWR2 in a similar fashion (hereafter referred to as HEK background). Both cell lines were positively selected for using 200 lg/mL hygromycin B. Immunocytochemistry. HEK cells were transfected in 6-well plates on PDL-coated coverslips. Cells were fixated with 4% paraformaldehyde in PBS for 10 min. on ice and 10 min. at RT followed by two times wash in PBS. Cells were either non-permeabilized to enable antibody labelling of only surface-expressed pool of receptors or permeabilized with 0.2% saponin in PBS for 30 min. to enable antibody labelling of the total pool of receptor, and then, all coverslips were blocked with 5% goat serum in PBS (blocking buffer) for 20 min. Cells were then incubated with primary mouse-anti-c-myc (clone 9E10) (Sigma, St. Louis, MO, USA) antibody (1:500 in blocking buffer), for 1 hr followed by extensive washing in blocking buffer. After washing, the cells were incubated with secondary goat anti-mouse-Alexa-488 conjugated antibody (Life Technologies) (1:500 in blocking buffer) for 30 min. Finally, cells were rinsed in PBS and mounted with ProLong antifade (Life Technologies). Cells were visualized using a Zeiss LSM 510 inverted confocal laser scanning microscope (Zeiss, Thornwood, NY, USA) equipped with an oil-immersion NA 1.4 639 objective and 488 nm lasers with appropriate emission filters. Processing of images was performed using ImageJ (NIH).
FMP assay. The FMP assay was performed as described previously with a few modifications [27] . Briefly, HEK cells were transfected and 16-24 hr later plated (50,000 cells/well in DMEM) into black PDLcoated 96-well plates with clear bottom (VWR, Radnor, PA, USA). Media was aspirated 16-20 hr later, and cells were washed in 100 lL/ well assay buffer (HBSS supplemented with 20 mM HEPES, adjusted to pH 7.4 and freshly supplemented with 2 mM CaCl 2 and 0.5 mM MgCl 2 ) followed by addition of 100 lL/well of FMP blue dye (0.5 mg/ mL) diluted in assay buffer. Then, plates were incubated at 37°C, 5% CO 2 , shielded from light. Ligand solutions were prepared in assay buffer, containing GABA EC [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] for positive allosteric modulators and GABA EC 80 for negative allosteric modulators and added to a ligand plate, which was placed in the NOVOStar TM plate reader (BMG LABTECH GmbH, Offenburg, Germany) pre-heated to 37°C, unless otherwise stated, for 10-15 min. before reading of the plate. After incubation, the cell plate was read using an emission wavelength of 560 nm and an excitation wavelength of 530 nm, detecting the response as changes in fluorescent signal given in fluorescence units (DFU). 25 lL of ligand solution was added to the cell plate, and the signal was measured for 33.8 sec. The experiments were performed in triplicate at least three times for each compound at the given receptors.
Whole-cell patch clamp electrophysiology. GABA-induced currents in GABA A receptor-expressing HEK293 Flp-In TM cells (either HEK-d or HEK background) were measured at 19-24°C using the whole-cell patch clamp technique. Voltage protocol and data acquisition were controlled using an Axopatch 200B amplifier, a Digidata 1440A and MiniDigi 1B A/D interface (Axon Instruments, Foster City, CA, USA), and pCLAMP 10 software (Axon Instruments). Recording electrodes had resistances of 2-4 MO. Series resistance was 70% compensated for. Currents were sampled at 10 kHz and low passfiltered at 2 kHz. The extracellular solution was composed of (in mM) 140 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgCl 2 , 11 glucose and 10 HEPES, adjusted to pH 7.4 with NaOH. The electrode solution was composed of (in mM) 4 NaCl, 135 CsCl, 2 MgCl 2 , 2 Mg 2 ATP, 0.5 GTP, 0.1 EGTA, 2.5 phosphocreatine-Na 2 and 10 HEPES, adjusted to pH 7.3 with CsOH. Cells were seeded on glass cover slips 1-5 hr prior to recordings, and a cover slip was placed in a 90-lL recording chamber (RC25, Warner Instruments, Hamden, CT, USA), voltage clamped at À50 mV and continuously superfused (~1 mL/min) with control or test solutions. Receptor agonists, modulators and antagonists were focally applied by means of the application cannula (inner diameter 100 lL) of an eight-channel pinch valve controlled pressurized perfusion system (VC3-8xP; ALA Scientific Instruments Inc., Farmingdale, NY, USA). The solution exchange time was estimated from the 10-90% rise times of the peak response to a dilute external solution. The rise times were consistently in the range of 100-150 ms.
Data analysis. Data and statistical analysis were carried out with GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, CA, USA). Means were compared and analysed statistically by either unpaired Student's t-test or one-way ANOVA followed by Dunnett's multiple comparison test as appropriate. The significance level was set at p < 0.05.
Data from the FMP assay were analysed as relative changes in fluorescence signal (ΔFU) by taking the maximum or minimum peak/plateau signal for compounds that, respectively, depolarized (positive ΔFU) and hyperpolarized (negative ΔFU) the cell membrane and subtracting the baseline signal. Changes in the fluorescent signal due to addition of ligand/buffer solution were manually omitted from the analysis, along with artefacts.
Concentration-response curves for agonists obtained in the FMP assay were fitted to the four-parameter concentration-response curve:
with 'bottom' representing the lower plateau response, 'top' the upper plateau response, '[A]' the logarithmic concentration of ligand and n H the Hill slope, representing the steepness of the curve. EC 50 is the concentration giving a response halfway between top and bottom. Similarly, concentration-response curves for antagonists were fitted to the same equation but with logIC 50 instead of logEC 50 . When appropriate, data were normalized to either a saturating concentration of GABA or the GABA response used for modulation. In whole-cell patch clamp recordings, data acquisition and analysis were performed with pCLAMP software 10.0 (Axon Instruments). Data plotting and statistical analyses were carried out with Origin 6.1 (OriginLab, MA, USA) and GraphPad Prism 6.0. Concentration-response curve fitting was carried out with GraphPad Prism using a nonlinear least square method to fit the data to the Hill equation:
where I is the peak amplitude of a current activated by a given concentration of agonist, I max is the maximal current produced by a satu- fig. 3A,B) . In comparison, mock-transfected HEKd cells were completely unresponsive to both GABA and PTX (data not shown). The determined IC 50 values for PTX at a 4 b 3 d receptors (1:1 transfection ratio) and homopentameric b 3 -complexes were 2.75 lM (pEC 50 AE S.E.M.; 5.56 AE 0.22, n = 3) and 1.45 lM (5.84 AE 0.24, n = 4), respectively, thus confirming our hypothesis (Student's t-test p = 0.45). Based on these results, the amount of b 3 -subunit cDNA used for transfection was titrated by systematically varying the amount of b 3 -subunit cDNA while keeping the amount of a 4 -subunit cDNA constant at 1 lg and adding up to a total of 2 lg cDNA with empty vector ( fig. 3C ) (transfection was performed in a 6-well plate with a total of 2 lg cDNA). A reduction in the amount of b 3 -subunit cDNA resulted in a gradually higher GABA response as well as less constitutive activity as seen by the action of PTX. The a 4 b 3 transfection ratio for the next experiments was thus chosen to be 2 lg a 4 + 0.01 lg b 3 cDNA (fig. 3C) 
In the FMP assay, the potency of GABA was first determined at the ternary receptors having EC 50 values of 0.30 lM fig. 4A,B,  table 1 ). Altogether, this shows that the binary receptors can be distinguished from the d-containing receptors in the FMP assay, as the d-containing receptors have a higher sensitivity to activation by both GABA and THIP.
Additionally, by comparing both the maximum GABA-elicited responses and the kinetic profiles detected in the FMP assay, a marked difference between the ternary d-containing receptors and the binary receptors was found. When conducting the assay in the same plate, the maximum response of GABA arising from a 4 b 1 was approximately 47% of that from 1 d receptors (fig. 5A,B, table 1) . In contrast to the data obtained using the FMP assay, the maximum response of THIP measured in patch clamp corresponded to 155% of the maximum GABA response, thus demonstrating superagonist effects of THIP. Additionally, kinetic traces of 20-sec. current responses to saturating GABA concentrations at a 4 b 1 and a 4 b 1 d receptors measured using whole-cell patch clamp consistently showed that currents at a 4 b 1 receptors displayed apparently smaller maximal currents and had distinct faster desensitization kinetics (current at 5 sec. relative to peak current 23% AE 3.4, n = 4) compared to a 4 b 1 d receptors (current at 5 sec. relative to peak current 59% AE 1.4, n = 4); (**p < 0.003) ( fig. 5C ). Further, we tested the d-selective compound DS2 in patch clamp electrophysiology at a 4 b 1 d receptors and showed that DS2 can potentiate the response of a low concentration (1 lM) of GABA as 2 lM and 5 lM DS2 potentiated the response by 215% AE 14.6, n = 8, and 356% AE 34.0, n = 9, respectively ( fig. 5d ).
Pharmacological profiles of reported d-preferring compounds.
Having validated the expression system and confirmed that a 4 b 1/3 d receptors can be suitably studied in the FMP assay, we tested the two reported d-preferring/selective compounds AA29504 [23] , an analogue of retigabine (positive allosteric modulator) [33] Using confocal microscopy combined with immunocytochemistry, we have shown that the d-subunit is expressed on the cell surface of HEK-d cells expressing a 4 b 1/3 d receptors, but also in HEK-d cells transfected with empty vector. This shows that the presence of an a-and a b-subunit is not required for the d-subunit to reach the cell surface. This is in contrast to the general belief that co-expression of both an asubunit and a b-subunit is required for the d-subunit to be surface-expressed [13, 34] . However, a recent study by Botzolakis et al. [35] has shown that the d-subunit is surfaceexpressed when transfected alone and that the level of surface expression was not affected by co-transfection with either a 1 -and b 2 -subunits alone or in combination. Our findings thus indicate that the Flp-In system promotes high expression levels.
Several studies have focused on the importance of transfection ratios -especially the amount of d-subunit vector used to express extrasynaptic d-containing GABA A receptors, but with conflicting conclusions [14, 16, 18] . In our study, we demonstrate that the amount of b 3 -subunit influences the expressed receptor population, as high levels of b 3 -subunit results in interfering signals from constitutively active homomeric b 3 -receptor complexes. The b 3 homomeric pharmacology was obvious from the absence of GABA sensitivity, the presence of PTX sensitivity and the high level of constitutive activity as reported in the literature [29, 36] . However, for the b 1 -subunit, we did not see any constitutive activity as well as no GABA sensitivity. Additionally, by titrating the level of b 3 -subunit used to transfect, we were able to limit the formation of b 3 homomeric receptors and thus remove the constitutive activity allowing us to study the a 4 b 1/3 d receptors selectively. It cannot be stressed enough how important careful optimization of expression conditions is to have control of the receptor subtype studies [10, 14, [16] [17] [18] .
The pharmacological studies of a 4 b 1/3 d receptors in the FMP assay show that d-containing receptors exhibit traditional dpharmacology, and can be distinguished pharmacologically from binary a 4 b 1/3 receptors. Furthermore, the expected b subunit pharmacology was confirmed using etomidate, which displayed an expected higher potency at b 3 versus b 1 -containing subtypes [32] . However, the potencies of GABA and THIP at a 4 b 1 d receptors determined in patch clamp electrophysiology were 5-8 times higher than that found using the FMP assay. Although we observed differences in the potency between the two assays, the FMP data are still within the range of what is reported in the literature, ranging from 0.89 to 2.02 lM [9, 11, 37, 38] and the difference between the potency of GABA and THIP is similar for both assays with THIP being 7 and 13 times less potent at a 4 b 1 d receptors in the FMP and patch clamp assays, respectively. Additionally, no superagonism of THIP was found in the FMP assay at either of the studied ternary d-receptors, in contrast to the patch clamp studies on a 4 b 1 d, where THIP was able to induce higher signals than GABA. This can be explained by a limitation of the FMP assay that has been noted before, as a study by Ghisdal et al. [26] found that the FMP assay was not suitable to compare the efficacy of GABA A positive allosteric modulators on a 1 b 2 c 2 receptors. The results obtained for DS2 likewise demonstrate this limitation in the assay, as the %-modulation measured in the FMP assay is markedly lower compared to patch clamp studies, indicating a lower sensitivity of the assay. This inability to pick up THIP superagonism in the FMP assay may also be speculated to influence the measured EC 50 value. The reason for this limitation in the assay can be inherent differences in the two methods, with the FMP assay detecting changes in membrane potential for an average cell population through changes in fluorescence, thus being an indirect measure in which the membrane potential of the cells is not clamped. In contrast, in whole-cell patch clamp recordings are performed on single cells with a clamped membrane potential. Thus, no final conclusions about the absolute efficacy of a compound can be made based on the results from the FMP assay, whereas the potency seems to be comparable to that determined with traditional electrophysiology. Whereas others have reported the existence of biphasic stimulation curves for GABA and low nanomolar potencies at human a 4 b 1/3 d GABA A receptors when measured by two-electrode voltage clamp in Xenopus laevis oocytes [10, 11] , we never observed this phenomenon using our HEK cell-based assays. Thus, it appears that the biphasic behaviour relates to the use of the oocyte expression system. Further, we have shown that the FMP assay can provide useful information on subtype pharmacology based on the kinetic profile obtained. Comparison of the kinetics of the voltage-gated human ether-a-go-go-like potassium channel obtained in the FMP assay and patch clamp electrophysiology showed comparable features [39] . Hence, the time-response curves might reflect the kinetics of the ion channel. However, no definite association to desensitization can be made based on the time-response curves, as desensitization is a feature determined by whole-cell patch clamp electrophysiology [25] . Based on this hypothesis, the observed difference in the timeresponse curves might be a result of the characteristic faster receptor desensitization of the binary receptor, resulting in dye exiting the cell and a decrease in the fluorescent signal. In contrast, no decrease in fluorescent signal was observed for the cells expressing d-containing receptors, probably due to slower desensitization [12, 25] . This observation is in agreement with the data obtained in patch clamp electrophysiology as well as data from others showing that the presence of the d-subunit results in a markedly slower desensitization compared to the binary receptors [13, 15, 19, 40] . Collectively, this suggests that the time-response curves of the fluorescence signals obtained in the FMP assay could give an indication of the kinetics of the ion channels and also be used to validate that the ligand effects are receptor-mediated.
After having validated the cell line as well as the assay, we probed the d-selectivity of the two reported d-selective compounds AA29504 [23] and 3-OH-2 0 MeO6MF [24] at a 4 b 3 and a 4 b 3 d receptors. AA29504 showed a small but significant preference for activation of the d-containing receptor but only with a 3.1 times difference in potency. The available data on the function and selectivity of AA29504 are sparse as the effect is only reported at a 4 b 3 d and a1b3c2S receptors, at which AA29504 increases the potency of GABA and THIP, at both receptor subtypes [23] . However, unpublished data from experiments in Xenopus laevis oocytes indicate that the effect of AA29504 is stronger at d-containing receptors compared to ab-receptors [41] , which is in agreement with the obtained results. Furthermore, no difference in potency was observed for the direct agonist effect 3-OH-2 0 MeO6MF, although it is reported to have no activity at binary a 4 b 3 receptors [24] . The data indicate that both compounds are more efficacious at the binary receptors. Both the expression system and the FMP assay are endowed with both advantages and limitations. One obvious advantage of the established d-expression system is the flexibility it provides. Specifically, it offers the opportunity to study subtypes with different a and b subunits and/or exchanging wildtype subunits for mutated subunits by easy co-transfection into the parent cell line. Used in conjunction with the established FMP assay, the set-up is suitable both for studies on structure-activity relationships, selectivity and mechanism of action. A major strength of the assay is the aforementioned throughput and the simplicity of the assay, making it especially useful for screening compound libraries to identify novel chemotypes. As very few d-selective compounds are currently available, such screening efforts may lead to the future identification of compounds that can aid in obtaining more insight into the role of d-containing receptors. Still, it remains crucial to further test new compounds in more traditional set-ups such as electrophysiology or radioligand binding assays, or preferably, in newer more physiologically relevant assays measuring, for example, dynamic redistribution events [42] . Potentially, screening efforts could lead to the identification of selective d-antagonists, which would be of great value to elucidate the functional importance of tonic inhibition and, possibly also, of therapeutic value in conditions with excessive tonic inhibition [4] . For example, d-inhibition has been reported as a scheme for promoting functional recovery in stroke [8] , and in specific subtypes of absence epilepsy, there is an associated excessive d-mediated tonic currents in the thalamus [43] .
As already alluded to, the assay is also endowed with some limitations. One notable limitation is the lack of accuracy in determining the efficacy of agonists and modulators. Another limitation relates to the inbuilt fluorescence measurements that may give false-negative or false-positive results. This problem may, however, be partially reduced by careful inspection of the time-response of the kinetic traces that may be used to rule out false-positive hits from, for example, quenching of the fluorescence. Finally, the assay suffers from the limitation that it is based on an indirect measurement of receptor activity and does not reflect directly kinetics such as effects on desensitization and deactivation times.
In conclusion, we have set up a facile fluorescence-based FMP assay for studying a 4 b 1/3 d receptors in HEK293 Flp-In TM cells and validated the d subunit expression, pharmacology and subtype composition. Although the receptor activity in the FMP assay is measured indirectly using a voltage-sensitive dye and in a whole-cell population, the potency and apparent kinetic traces are qualitatively similar to more direct electrophysiology recordings. Conveniently, the use of a d-subunit stable cell line with transient expression of a-and b-subunits allows for a flexible recombinant set-up for evaluation of different d-containing subtypes with both wild-type or mutated a and b-subunits. 
